Less than 3% of gynecologic malignancies and 3 to 7% of uterine malignancies are uterine sarcomas (US), which are uncommon tumors. The US is known for its aggressive nature and high risk of local and metastatic disease recurrence. In addition, their management is poorly standardized. Our study’s objective was to look at US health care’s epidemiological, clinical, therapeutic, and prognostic aspects of US health care.

This monocentric, descriptive, and retrospective analysis included patients with the US treated between 2000 and 2020 at the Salah Azaiez Tunisian oncological center.

About 103 participants participated in the trial. The age was 50 on average. The primary finding factor (n=70) was menometrorrhagia. The diagnosis was made after surgery in 73.8% of patients. On 82 individuals’ hysterectomy specimens, histological confirmation was performed. Leiomyosarcoma, which was present in 72.8% of patients, was the most common histological type. The majority (41.7%) were from Stage I. Surgery was performed on 97 patients, 87 of whom received a complete hysterectomy along with bilateral salpingo-oophorectomy and lymph node dissection. Around 16.5% of cases required adjuvant chemotherapy. In addition, 35 individuals had adjuvant pelvic radiation. First-line chemotherapy was administered to 31 individuals. In 82.3% of instances, doxorubicin and ifosfamide were administered together as the protocol. Following progression to first line, two patients had palliative endocrine treatment. The overall survival at 2 and 5 years, including all stages, after a median follow-up of 56 months was 56% and 40%, respectively. At 2 and 3 years, the overall survival rate for metastatic stages was 36% and 25%. There were no prognostic factors found in the multivariate analysis. At 3 and 5 years, progression-free survival was 82% and 72%, respectively. Only the circumstances surrounding the finding were identified as prognostic factors affecting progression-free survival in the multivariate analysis (P=0.042).

US is a specific kind of tumor. To more effectively codify its management, prospective randomized trials are required.

Reference: annalsofoncology.org/article/S0923-7534(22)00729-3/fulltext